Phase 3
Completed N=114
Pilot Study of Minocycline in Huntington's Disease
Huntington Disease
Source: ClinicalTrials.gov NCT00277355 ↗
Enrolled (actual)
114
Serious AEs
10.5%
Results posted
Apr 2013
Primary outcomePrimary: Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method] — 1.55; 1.15 units on a scale
Summary
This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD. We will measure the effect of minocycline on HD by measuring the change in Huntington's disease symptoms.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method] |
1.55; 1.15 | — |
| SECONDARY Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method] |
1.71; 1.15 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 years or older
- Clinical features of HD and a confirmatory family history of HD; and/or genetically confirmed HD
- Independently walking and fully self-sufficient in activities of daily living (eating, dressing, bathing)
- Able to take medication (capsules) by mouth
Exclusion Criteria
- History of known hypersensitivity or intolerability to minocycline or known allergy to any tetracycline
- History of vestibular disease
- Subjects with underlying hematologic, hepatic or renal disease
- History of systemic lupus erythematosus (SLE)
Data sourced from ClinicalTrials.gov (NCT00277355). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.